Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

High Throughput Imaging Speeds Analysis of Hormone Receptors

By Drug Discovery Trends Editor | November 3, 2008

A new high throughput microscopy technique enabled researchers at Baylor College of Medicine in Houston to analyze thousands of individual cells expressing androgen receptor, a finding that could herald new ways of evaluating the effect of drugs or other treatments on cells with normal or aberrant hormone receptors.

In a report in the current issue of Public Library of Science One (PLoS One), Dr. Michael Mancini and his collaborators reported a new, next generation high throughput image-based assay that helps determine the level and location of androgen receptor and its transcriptional activity on a cell-by-cell basis.

Tie to personalized medicine
‘This has application to personalized medicine,’ said Mancini, associate professor of molecular and cellular biology at BCM and director of its Integrated Microscopy Core. ‘For example, we could use the high throughput microscope and robust image analysis to determine which drug might be best to turn off or repair a mutated cell that is causing disease.’

In this case, he and his colleagues analyzed the androgen receptor, a molecule that binds the hormones testosterone or dihydrotestosterone and is responsible for regulating genes that give an organism or animal male characteristics.

Customized approach
‘As our ability to image cells using high throughput microscopy got going faster and faster, we began to collect enormous amounts of functional data that was usually only accessible by separate (and slow) biochemical experiments. Our customized software approaches then allowed us to assemble the results into a more systems-level appreciation of the biology, linking together several functional characteristics of the androgen receptor,’ he said.

The high throughput technique, often called high content analysis, enables researchers to analyze effects on a cell-by-cell basis, taking into account the heterogeneity of the cells, he said. Before the development of new microscopes, he said, taking a few images an hour was a feat.

‘Now we routinely take thousands of pictures a day,’ said Mancini.
Not only that, but scientists such as Adam Szafran, the M.D./Ph.D. student who is first author of this report, can essentially look at several elements of cellular response at the same time.

Cell cycle
‘We can study issues dealing with the cell cycle as it goes through its life,’ said Szafran. Previously, scientists had to manipulate cells to capture them at different points in their lives. The new imaging technology enables them to study the cell in a more natural form.

In the PLoS study, Szafran, Mancini and their colleagues were able to study the response of a particular androgen mutation to different ligands (molecules that can trigger binding to a particular protein).

‘We could show how the receptor was defective in respect to the endogenous (or normally present) ligand. When we used a different ligand, we could rescue aspects of the receptor’s function,’ said Szafran.

One day, physicians could take the individual cells of a patient diagnosed with a disease and use the high throughput microscope to see how different drugs affect the mutated cells. The high speed approaches for androgen receptor studies are also being used to investigate basic science and personalized medicine possibilities in several other projects, including breast and prostate cancers, and adipose (fat cell) biology.

Release Date: November 1, 2008
Source: Baylor College of Medicine


Filed Under: Drug Discovery

 

Related Articles Read More >

S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
Drug companies sign “Most Favored Nation” deals, then raise prices anyway
New gonorrhea antibiotic could treat resistant infections
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE